A Novel Antibody-drug Conjugate: OBI-999
OBI PHARMA, INC.
A Novel Antibody-drug Conjugate: OBI-999
OBI PHARMA, INC.
Back to Hall of Fame
Globo H (GH) is highly expressed in common epithelial cancer cells but is expressed at low levels in normal tissues. Therefore, it is a novel target for developing anticancer agents. The design of OBI-999 is to conjugate GH specific antibody with cytotoxic payload, which can target GH expressing cancer cells and delivers toxin to eliminate the cells. OBI-999 will be the first in class agent for treating high GH expression cancers.
Highlights
- OBI-999 belongs to a class of Antibody Drug Conjugates (ADCs) anti-cancer agents and there are 5 ADCs that were approved by FDA in 2019 and 2020. Treatment with ADC provides better safety margin and efficacy than chemotherapy due to antigen specificity. Therefore, OBI-999 should be able to improve the quality of life and life expansion of patients, which will relieve the burden of the patient’s families.
- OBI-999 demonstrated excellent efficacy in suppressing the tumour growth in four animal models.
- OBI-999 received FDA orphan drug designation for pancreatic and gastric cancers.
View Website
Back to Hall of Fame
Globo H (GH) is highly expressed in common epithelial cancer cells but is expressed at low levels in normal tissues. Therefore, it is a novel target for developing anticancer agents. The design of OBI-999 is to conjugate GH specific antibody with cytotoxic payload, which can target GH expressing cancer cells and delivers toxin to eliminate the cells. OBI-999 will be the first in class agent for treating high GH expression cancers.
Highlights
- OBI-999 belongs to a class of Antibody Drug Conjugates (ADCs) anti-cancer agents and there are 5 ADCs that were approved by FDA in 2019 and 2020. Treatment with ADC provides better safety margin and efficacy than chemotherapy due to antigen specificity. Therefore, OBI-999 should be able to improve the quality of life and life expansion of patients, which will relieve the burden of the patient’s families.
- OBI-999 demonstrated excellent efficacy in suppressing the tumour growth in four animal models.
- OBI-999 received FDA orphan drug designation for pancreatic and gastric cancers.